F. Cajade, M. Touris Lores, I. Soto-Baselga, B. Bernárdez-Ferrán, S. Santana-Martínez, I. Zarra-Ferro
{"title":"5PSQ-115 利用欧洲不良反应数据库(EudraVigilance)评估与阿帕鲁胺和恩扎鲁胺治疗转移性前列腺癌相关的甲状腺功能减退症","authors":"F. Cajade, M. Touris Lores, I. Soto-Baselga, B. Bernárdez-Ferrán, S. Santana-Martínez, I. Zarra-Ferro","doi":"10.1136/ejhpharm-2024-eahp.449","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":107680,"journal":{"name":"Section 5: Patient safety and quality assurance","volume":"143 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"5PSQ-115 Evaluation of hypothyroidism associated with apalutamide and enzalutamide treatment in metastatic prostate cancer using the European adverse effect database (EudraVigilance)\",\"authors\":\"F. Cajade, M. Touris Lores, I. Soto-Baselga, B. Bernárdez-Ferrán, S. Santana-Martínez, I. Zarra-Ferro\",\"doi\":\"10.1136/ejhpharm-2024-eahp.449\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":107680,\"journal\":{\"name\":\"Section 5: Patient safety and quality assurance\",\"volume\":\"143 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Section 5: Patient safety and quality assurance\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ejhpharm-2024-eahp.449\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Section 5: Patient safety and quality assurance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2024-eahp.449","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
5PSQ-115 Evaluation of hypothyroidism associated with apalutamide and enzalutamide treatment in metastatic prostate cancer using the European adverse effect database (EudraVigilance)